Clinical and pharmacological group: & nbsp

Other neurotropic drugs

Included in the formulation
  • Acathinol Memantine
    pills inwards 
    MERCZ PHARMA, LLC     Russia
  • Acathinol Memantine
    pills inwards 
  • Alzheim
    pills inwards 
    Laboratorios Bago S.A.     Argentina
  • Auranex
    solution inwards 
  • Maruksa®
    pills inwards 
    KRKA-RUS, LLC     Russia
  • Maruksa®
    pills inwards 
    KRKA-RUS, LLC     Russia
  • Memaneirin
    drops inwards 
    BIS, CJSC     Russia
  • Memantal®
    pills inwards 
  • Memantine
    pills inwards 
  • Memantine
    pills inwards 
    VERTEKS, AO     Russia
  • Memantine
    pills inwards 
  • Memantine
    pills inwards 
  • Memantine
    pills inwards 
    ATOLL, LLC     Russia
  • Memantine Canon
    pills inwards 
  • Memantine Canon
    pills inwards 
  • Memantine Canon
    pills inwards 
  • Memantine Sandoz®
    pills inwards 
    Sandoz d.     Slovenia
  • Memantine Sandoz®
    pills inwards 
    Sandoz d.     Slovenia
  • Memantine-Alvogen
    pills inwards 
    Alvogen IPKo S.A.L.     Luxembourg
  • Memantine Richter
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Memantine-TL
    pills inwards 
  • Memantinol®
    pills inwards 
    Farm-Holding, CJSC     Russia
  • Mémique
    pills inwards 
  • Memorel®
    pills inwards 
    NIZHFARM, JSC     Russia
  • Noogeron
    pills inwards 
  • Noogeron-Teva
    pills inwards 
  • Tingrex®
    pills inwards 
    GRINDEX, JSC     Latvia
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    N.06.D.X.01   Memantine

    N.06.D.X   Other drugs for the treatment of dementia

    Pharmacodynamics:

    A noncompetitive antagonist of glutamate N-methyl-D-aspartate (NMDA) -receptors, inhibits glutamatergic neurotransmission and the progression of neurodegenerative processes, exerts a neuromodulatory effect. Reduces the excessive stimulating effect of cortical glutamate neurons on the neostriatum with insufficient allocation of dopamine. Reducing the flow of calcium ions into neurons, prevents their destruction.

    Has cerebrovazodilatiruyuschee, nootropic, psychostimulating and antihypoxic action. It improves memory and concentration, reduces depressive symptoms and fatigue, and also prevents spasticity,caused by damage and brain diseases.

    Pharmacokinetics:

    After oral administration, up to 80% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 2-6 hours. The connection with plasma proteins is 45%.

    Therapeutic effect develops after the reception. Metabolism in the liver to inactive metabolites.

    The half-life is 60-100 hours. Elimination by the kidneys.

    Indications:

    It is used for the treatment of moderate and severe dementia in Alzheimer's disease.

    V.F00-F09.F00 *   Dementia in Alzheimer's disease (G30 .- +)

    VI.G30-G32.G30   Alzheimer's disease

    Contraindications:

    Hepatic insufficiency of a serious degree, an individual intolerance, a children's age till 18 years.

    Carefully:

    Renal failure, epilepsy, thyrotoxicosis, arterial hypertension, history of convulsions, heart failure, myocardial infarction in history, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category B. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Inside, regardless of the time of ingestion with an initial dose of 5 mg once a day, at the same time. After 1 week, the dose rises to 10 mg, during the third week - 15 mg, at the 4th week - 20 mg.

    The highest daily dose: 20 mg.

    The highest single dose: 20 mg.

    Side effects:

    Central and peripheral nervous system: headache, drowsiness, dizziness, rarely - hallucinations, gait disturbance, convulsions.

    The cardiovascular system: arterial hypertension, thromboembolism.

    Digestive system: constipation, rarely - nausea and vomiting, pancreatitis.

    Allergic reactions.

    Overdose:

    Dizziness, tremor, confusion, aggressiveness, agitation, convulsions, psychosis, stupor, hallucinations, gait unsteadiness, vomiting, diarrhea.

    Treatment is symptomatic.

    Interaction:

    Reduces the effects of neuroleptics and barbiturates.

    Enhances the action of levodopa.

    Reduces the concentration of hydrochlorothiazide in blood plasma.

    Reduces the concentration of ranitidine, procainamide, quinidine, cimetidine and nicotine in the blood plasma.

    Simultaneous application with amantadine, dextromethorphan, ketamine, phenytoin increases the risk of developing psychosis.

    Special instructions:

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up